Brief: VectivBio Presents Preclinical Data Supporting Apraglutide For Treatment Of Acute Graft-Versus-Host Disease At 48Th Annual Meeting Of European Society For Blood And Marrow Transplantation
23/03/2022 11:22
March 23 (Reuters) - VectivBio Holding AG VECT.O :
* VECTIVBIO PRESENTS PRECLINICAL DATA SUPPORTING APRAGLUTIDE
FOR
TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE AT THE 48TH ANNUAL
MEETING OF THE EUROPEAN SOCIETY FOR BLOOD AND MARROW
TRANSPLANTATION
Source text for Eikon: ID:nGNX3QfLzf
Further company coverage: VECT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on VectivBio Holding AG
See all newsBrief: Ironwood And VectivBio Announce Expiration Of Hart-Scott-Rodino Waiting Period For Proposed Acquisition Of VectivBio
Brief: Ironwood Pharmaceuticals Says If Deal Aborts, VectivBio To Pay Termination Fee
U.S. STOCKS ON THE MOVE-Pfizer, Zoom Video, American Airlines
U.S. STOCKS ON THE MOVE-Atea Pharma, Microbot Medical, Krystal
U.S. STOCKS ON THE MOVE-NuScale Power Corp, Foot Locker, Greenhill